Mesoblast (MEOBF) Long-Term Deferred Tax (2017 - 2021)
Mesoblast's (MEOBF) quarterly Long-Term Deferred Tax came in at $80.2 million in Q4 2021, little changed year-over-year from $80.1 million in Q4 2020, and little changed quarter-over-quarter from $80.2 million in Q3 2021.
Analysis
Mesoblast (MEOBF) Long-Term Deferred Tax (2017 - 2021) Analysis & Trends
Mesoblast has disclosed Long-Term Deferred Tax across 5 years of filings, most recently posting $80.2 million for Q4 2021.
- In Q4 2021, Long-Term Deferred Tax changed 0.11% year-over-year to $80.2 million; the TTM figure through Dec 2021 stood at $80.2 million (changed 0.11% YoY), while the FY2021 annual figure was $80.2 million, up 1.35% from the prior year.
- Long-Term Deferred Tax came in at $80.2 million for Q4 2021 at Mesoblast, roughly flat from $80.2 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $80.2 million in Q3 2021 to a low of $56.6 million in Q2 2018.
- Average Long-Term Deferred Tax over 5 years is $73.2 million, with a median of $78.2 million recorded in 2017.
- Year-over-year, Long-Term Deferred Tax declined 27.68% in 2018 and rose 21.22% in 2019.
- Over 5 years, Long-Term Deferred Tax stood at $78.2 million in 2017, then slipped by 23.17% to $60.1 million in 2018, then rose by 21.22% to $72.9 million in 2019, then grew by 9.97% to $80.1 million in 2020, then advanced by 0.11% to $80.2 million in 2021.
- Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $80.2 million in Q4 2021, $80.2 million in Q3 2021, and $80.2 million in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 80.21 Mn |
| Sep 30, 2021 | 80.25 Mn |
| Jun 30, 2021 | 80.16 Mn |
| Mar 31, 2021 | 80.20 Mn |
| Dec 31, 2020 | 80.12 Mn |
| Sep 30, 2020 | 79.91 Mn |
| Jun 30, 2020 | 79.10 Mn |
| Mar 31, 2020 | 74.78 Mn |
| Dec 31, 2019 | 72.85 Mn |
| Sep 30, 2019 | 67.45 Mn |
| Jun 30, 2019 | 65.43 Mn |
| Mar 31, 2019 | 62.28 Mn |
| Dec 31, 2018 | 60.10 Mn |
| Jun 30, 2018 | 56.57 Mn |
| Jun 30, 2017 | 78.23 Mn |